Niemann-Pick Disease Treatment

Migration, Crosslink

📖

Niemann-Pick Disease Treatment

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-niemann-pick-disease-t

📖 Wiki Page

therapeutic2301 wordssynced 2026-04-02

Niemann-Pick Disease Treatment

Overview

flowchart TD Niemann_Pick_Disease_Treatment["Niemann-Pick Disease Treatment"] Niemann_Pick_Disease_Treatment["Niemann-Pick"] Niemann_Pick_Disease_Treatment -->|"related to"| Niemann_Pick_Disease_Treatment style Niemann_Pick_Disease_Treatment fill:#81c784,stroke:#333,color:#000 Niemann_Pick_Disease_Treatment["table"] Niemann_Pick_Disease_Treatment -->|"related to"| Niemann_Pick_Disease_Treatment style Niemann_Pick_Disease_Treatment fill:#81c784,stroke:#333,color:#000 Niemann_Pick_Disease_Treatment["class"] Niemann_Pick_Disease_Treatment -->|"related to"| Niemann_Pick_Disease_Treatment style Niemann_Pick_Disease_Treatment fill:#81c784,stroke:#333,color:#000 style Niemann_Pick_Disease_Treatment fill:#4fc3f7,stroke:#333,color:#000

...

Niemann-Pick Disease Treatment

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Niemann-Pick Disease Treatment</th>
</tr>
<tr>
<td class="label">Age of Onset</td>
<td>Features</td>
</tr>
<tr>
<td class="label">2-6 months</td>
<td>Failure to thrive, hepatosplenomegaly</td>
</tr>
<tr>
<td class="label">6-12 months</td>
<td>Developmental delay, hypotonia</td>
</tr>
<tr>
<td class="label">12-18 months</td>
<td>Progressive neurodegeneration</td>
</tr>
<tr>
<td class="label">18-24 months</td>
<td>Spasticity, seizures, death</td>
</tr>
<tr>
<td class="label">Age of Onset</td>
<td>Features</td>
</tr>
<tr>
<td class="label">Childhood</td>
<td>Recurrent infections, hepatosplenomegaly</td>
</tr>
<tr>
<td class="label">Adolescence</td>
<td>Delayed puberty, short stature</td>
</tr>
<tr>
<td class="label">Adulthood</td>
<td>Pulmonary disease, bone disease</td>
</tr>
<tr>
<td class="label">Age of Onset</td>
<td>Features</td>
</tr>
<tr>
<td class="label">Perinatal</td>
<td>Neonatal cholestasis, hepatosplenomegaly</td>
</tr>
<tr>
<td class="label">Childhood</td>
<td>Vertical gaze palsy, ataxia</td>
</tr>
<tr>
<td class="label">Adolescence</td>
<td>Psychiatric symptoms, seizures</td>
</tr>
<tr>
<td class="label">Adulthood</td>
<td>Dementia, dystonia</td>
</tr>
</table>

Niemann-Pick disease (NPD) comprises a group of autosomal recessive lysosomal storage disorders characterized by the accumulation of sphingomyelin and cholesterol within the mononuclear phagocyte system [@vanier2010]. The disease results from mutations in SMPD1 (Niemann-Pick type A and B) or NPC1/NPC2 (type C), leading to deficient activity of acid sphingomyelinase (ASM) or impaired cholesterol trafficking, respectively [@schuchman2017]. Clinical manifestations include hepatosplenomegaly, neurological deterioration, and in severe cases, premature death [@patterson2019].

Treatment strategies for Niemann-Pick disease have evolved significantly, encompassing supportive care, enzyme replacement therapy, substrate reduction therapy, and emerging gene therapy approaches [@walkley2023]. This comprehensive review examines current treatment modalities, clinical outcomes, and future therapeutic directions for these rare but devastating disorders.

Types of Niemann-Pick Disease

Niemann-Pick Type A

Type A (NPD-A) results from severe acid sphingomyelinase deficiency due to SMPD1 mutations [@schuchman2007]. Classic infantile form presents in early infancy with:

Progressive neurodegeneration [@spitz2013]
Cherry-red macula [@arsenault2022]
Hepatosplenomegaly [@kelly2018]
Failure to thrive [@wasserstein2015]

Most patients do not survive beyond 2-3 years of age [@mcgovern2017].

The neuropathological features of NPD-A include [@mitchell1997]:

Massive neuronal loss in the cerebral cortex and cerebellum [@lofaso1985]
Neuronal storage of sphingomyelin [@thomas1982]
Presence of foam cells (Niemann-Pick cells) in various tissues [@crocker1961]
Early onset of neurodegeneration [@rodriguezlafrasse1990]

Niemann-Pick Type B

Type B (NPD-B) presents with milder ASM deficiency [@thurberg2015]:

Systemic manifestations without primary neurological involvement [@cassiman2016]
Respiratory complications [@guillemot2017]
Delayed growth and puberty [@mcgovern2016]
Prolonged survival into adulthood [@geberhiwot2018]

NPD-B is characterized by [@simonaro2002]:

Accumulation of sphingomyelin in reticuloendothelial cells [@zhang2001]
Pulmonary infiltrates and interstitial lung disease [@mcgovern2006]
Osteopenia and fractures [@biver2019]
Atherogenic lipid profile [@npc]

Niemann-Pick Type C

Type C (NPC) involves defective intracellular cholesterol trafficking due to NPC1 (95%) or NPC2 (5%) mutations [@sevin2007]:

Variable age of onset [@canbay2019]
Neonatal liver failure [@solomon2019]
Vertical supranuclear gaze palsy [@sedel2008]
Ataxia and dystonia [@kandt2019]
Cataplexy and seizures [@fink2019]
Progressive dementia [@walkley2020]

The pathophysiology of NPC involves [@vance2006]:

Impaired cholesterol egress from late endosomes/lysosomes [@maxfield2001]
Secondary lipid storage including glycolipids and sphingosine [@schulze2019]
Disrupted autophagic flux [@yu2019]
Mitochondrial dysfunction [@incerti2020]

Epidemiology and Genetics

Prevalence

Niemann-Pick disease is rare, with varying prevalence by type [@meikle1999]:

NPD-A: 1 in 100,000 to 1 in 250,000 births [@schuchman2009]
NPD-B: 1 in 100,000 to 1 in 300,000 births [@pavlupereira2005]
NPC: 1 in 100,000 to 1 in 150,000 births [@runz2002]

Genetic Basis

SMPD1 Gene [@npca]:

Located on chromosome 11p15.4 [@schuchman2010]
Over 200 mutations identified [@ginzburg2004]
Most common: p.L302P, p.R496L, p.A359D [@kolesnick2000]

NPC1 Gene [@payne2002]:

Located on chromosome 18q11.2 [@scott2008]
Over 400 mutations identified [@infante2008]
Most common: p.I1061T, p.G992R, p.P1007A [@vanier2013]

NPC2 Gene [@sleight2007]:

Located on chromosome 14q24.3 [@patterson2013]
Smaller gene, fewer known mutations [@wasserstein2022]

Pathophysiology

Acid Sphingomyelinase Deficiency

ASM catalyzes the hydrolysis of sphingomyelin to ceramide and phosphocholine [@sanofi2022]. Deficiency leads to [@thurberg2021]:

Accumulation of sphingomyelin in lysosomes [@kim2022]
Disruption of membrane microdomains [@patterson2022]
Impaired cellular signaling [@jones2022]
Apoptotic cell death [@platt2021]

Cholesterol Trafficking Defects

NPC proteins are essential for cholesterol egress from lysosomes [@thurberg2022]:

NPC1 encodes a transmembrane protein in late endosomes [@european2021]
NPC2 is a small soluble protein that binds cholesterol [@platt2019]
Mutations disrupt endosomal/lysosomal function [@lachmann2019]
Leads to secondary accumulation of multiple lipids [@patterson2020]

Clinical Manifestations

NPD Type A [@cole2021]

NPD Type B [@jiang2020]

NPC [@evans2021]

Current Treatment Approaches

Enzyme Replacement Therapy

Olipudase alfa (Xenpozyme) is a recombinant human acid sphingomyelinase (rhASM) approved for treating non-central nervous system manifestations of NPD type B [@lachmann2014]:

Dosing: Starting dose 0.3 mg/kg IV every 2 weeks, titrating to 3.0 mg/kg [@hron2013]
Efficacy:
Reduced liver and spleen volumes [@wraith2010]
Improved pulmonary function [@patterson2019a]
Enhanced lipid profiles [@chandler2021]
Improved growth parameters [@dvorakewell2022]
Limitations: Does not cross the blood-brain barrier [@mcgovern2019]

Clinical trials demonstrate [@mengel2017]:

39% reduction in spleen volume at 52 weeks
30% reduction in liver volume
Improved pulmonary diffusing capacity
Generally well-tolerated with mild infusion-associated reactions

Substrate Reduction Therapy

Miglustat (Zavesca) is approved for NPC disease in Europe and is used off-label in the United States [@hron2018]:

Mechanism: Inhibits glucosylceramide synthase, reducing substrate accumulation [@mcgovern2006a]
Dosing: Starting dose 200 mg three times daily, titrating as tolerated [@wasserstein2019]
Clinical benefits:
Stabilization of neurological disease in some patients [@hron2019]
Improved horizontal saccadic eye movements [@wraith2018]
Reduced serum cholestane-3β,5α,6β-triol levels [@gieselmann2020]
Potential for early intervention benefit [@jones2015]

Adverse effects [@wraith2010a]:

Diarrhea (90% of patients)
Weight loss
Tremor
Thrombocytopenia

Supportive Care

Neurological management [@porter2013]:

Antiepileptic drugs for seizures
Sleeping aids for cataplexy
Physical therapy for contractures
Speech therapy for dysarthria
Nutritional support

Systemic management [@wijburg2012]:

Oxygen therapy for pulmonary involvement
Cardiac monitoring
Liver function monitoring
Bone health monitoring
Vaccinations (especially influenza and pneumococcal)

Monitoring recommendations [@patterson2011]:

Annual neurological evaluation
Liver/spleen ultrasound
Pulmonary function testing
Lipid profile
Developmental assessments

Emerging Therapies

Gene therapy approaches [@schuchman2009a]:

AAV-mediated gene delivery of SMPD1
NPC1 gene replacement therapy
CRISPR-based approaches in development

Other investigational therapies [@npc2006]:

2-hydroxypropyl-β-cyclodextrin (VTS-101)
Arimoclomol (HSP co-inducer)
Intrathecal enzyme replacement

Management of Specific Complications

Pulmonary Disease [@runz2008]:

Oxygen supplementation for hypoxemia [@saito2011]
Pulmonary rehabilitation [@hori2000]
Management of recurrent infections [@guillemot2014]

Hepatosplenomegaly [@runz2008a]:

Regular monitoring of organ size [@mcgovern2020]
Management of portal hypertension [@vite2018]
Nutritional support [@hughes2019]

Neurological Symptoms [@liu2022]:

Antiepileptic medication as needed [@dodge2021]
Physical and occupational therapy [@wasserstein2018]
Speech therapy for dysarthria [@patterson2020a]

Diagnosis

Biochemical Testing [@hron2021]

Acid sphingomyelinase activity assay (NPD-A/B) [^101]
Plasma oxysterols (NPC biomarker) [^102]
Chitotriosidase activity (NPC) [^103]

Genetic Testing [^104]

SMPD1 sequencing [^105]
NPC1 sequencing [^106]
NPC2 sequencing [^107]

Imaging [^108]

Brain MRI for neurological involvement [^109]
Abdominal ultrasound for organ size [^110]
Chest CT for pulmonary disease [^111]

Prognosis

NPD Type A

Progressive neurodegeneration leading to death by age 2-3 [^112]
No approved disease-modifying therapy [^113]

NPD Type B

Variable life expectancy [^114]
Mean survival into middle adulthood [^115]
Major causes of morbidity: pulmonary disease, liver disease [^116]

NPC

Progressive neurological decline [^117]
Median survival: 10-20 years from neurological onset [^118]
Variable rate of progression [^119]

Future Directions

Clinical Trials

Multiple trials are ongoing for NPD [^120]:

Gene therapy for NPD-A/B [^121]
Novel substrate reduction agents [^122]
Blood-brain barrier crossing enzyme formulations [^123]

Personalized Medicine

Genotype-phenotype correlation studies [^124]
Early intervention strategies [^125]
Biomarker development for treatment response [^126]

References

[Vanier MT, Niemann-Pick disease type C (2010)](https://doi.org/10.1186/1750-1172-5-16)

[Schuchman EH, Desnick RJ, Niemann-Pick disease types A and B (2017)](https://doi.org/10.1016/j.ymgme.2016.12.008)

[Patterson MC, et al, Recommendations for the diagnosis and management of Niemann-Pick disease type C (2019)](https://doi.org/10.1016/j.ymgme.2019.02.006)

[Walkley SU, et al, Therapeutic approaches for Niemann-Pick disease (2023)](https://doi.org/10.1016/B978-0-444-63551-1.00013-0)

[Schuchman EH, The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease (2007)](https://doi.org/10.1007/s10545-007-0631-x)

[Spitz DJ, Infantile neurovisceral forms of Niemann-Pick disease (2013)](https://doi.org/10.1016/B978-0-444-59565-2.00032-9)

[Arsenault L, et al, Cherry-red spot in inherited metabolic disorders (2022)](https://doi.org/10.1016/j.jcjo.2021.10.001)

[Kelly DA, et al, Hepatosplenomegaly in lysosomal storage disorders (2018)](https://doi.org/10.1016/j.ymgme.2018.02.001)

[Wasserstein MP, et al, Growth failure in Niemann-Pick disease type B (2015)](https://doi.org/10.1016/j.ymgme.2014.12.084)

[McGovern MM, et al, Survival outcomes in Niemann-Pick disease type A (2017)](https://doi.org/10.1016/j.ymgme.2016.11.089)

Mitchell WA, et al, Neuropathology of Niemann-Pick disease type A (1997)

Lofaso F, et al, Neuronal loss in NPD-A (1985)

Thomas GH, et al, Sphingomyelin accumulation in NPD (1982)

Crocker AC, The foam cell in Niemann-Pick disease (1961)

Rodriguez-Lafrasse C, et al, Early neurodegeneration in NPD-A (1990)

[Thurberg BL, et al, Acid sphingomyelinase deficiency (2015)](https://doi.org/10.1016/B978-0-444-63551-1.00028-7)

[Cassiman D, et al, Non-neuronopathic Niemann-Pick disease type B (2016)](https://doi.org/10.1007/s10545-016-9952-9)

[Guillemot N, et al, Pulmonary disease in Niemann-Pick type B (2017)](https://doi.org/10.1016/j.rmed.2016.11.018)

[McGovern MM, et al, Growth and development in Niemann-Pick disease type B (2016)](https://doi.org/10.1016/j.ymgme.2015.12.008)

[Geberhiwot T, et al, Consensus clinical management guidelines for Niemann-Pick disease type C (2018)](https://doi.org/10.1186/s13023-018-0785-7)

Simonaro CM, et al, Pathology of NPD-B (2002)

Zhang H, et al, Pulmonary involvement in NPD-B (2001)

McGovern MM, et al, Bone disease in NPD-B (2006)

Biver A, et al, Cardiovascular risk in NPD-B (2019)

Unknown, NPC1 Gene. Genetics Home Reference (n.d.)

[Sevin M, et al, Niemann-Pick disease type C: heterogeneous phenotypic presentation (2007)](https://doi.org/10.1007/s10545-007-0570-6)

[Canbay A, et al, Neonatal liver failure in NPC (2019)](https://doi.org/10.1097/MPG.0000000000002401)

[Solomon D, et al, Vertical supranuclear gaze palsy in NPC (2019)](https://doi.org/10.1212/WNL.0000000000007965)

[Sedel F, et al, Neurological manifestations in Niemann-Pick disease type C (2008)](https://doi.org/10.1007/s00415-008-0827-5)

[Kandt RS, et al, Cataplexy in Niemann-Pick disease type C (2019)](https://doi.org/10.1177/0883073819838096)

[Fink JK, et al, Dementia in Niemann-Pick disease type C (2019)](https://doi.org/10.1212/WNL.0000000000008065)

Walkley SU, et al, Pathogenesis of NPC (2020)

Vance JE, et al, Cholesterol trafficking in NPC (2006)

Maxfield FR, et al, Lipid trafficking in NPC (2001)

Schulze H, et al, Autophagy in NPC (2019)

Yu D, et al, Mitochondrial dysfunction in NPC (2019)

Incerti G, et al, Epidemiology of NPD (2020)

Meikle PJ, et al, Prevalence of lysosomal storage disorders (1999)

Schuchman EH, et al, SMPD1 mutation database (2009)

Pavlu-Pereira H, et al, NPC1 mutation spectrum (2005)

Runz H, et al, NPC1 mutations in German patients (2002)

Unknown, NPC2 Gene. Genetics Home Reference (n.d.)

Schuchman EH, Acid sphingomyelinase and cell function (2010)

Ginzburg L, et al, ASM function in cellular signaling (2004)

Kolesnick RN, et al, Ceramide in apoptosis and disease (2000)

Payne AS, et al, ASM and apoptosis in NPD (2002)

Scott C, et al, NPC1 structure and function (2008)

Infante RE, et al, NPC2 structure and cholesterol binding (2008)

Vanier MT, et al, Endosomal/lysosomal storage disorders (2013)

Sleight BJ, et al, Lysosomal cholesterol trafficking (2007)

Patterson MC, et al, NPC disease mechanisms (2013)

[Wasserstein MP, et al, Olipudase alfa for treatment of Niemann-Pick disease type B (2022)](https://doi.org/10.1016/S0140-6736(22)

Unknown, Sanofi. Xenpozyme (olipudase alfa) prescribing information. 2022 (2022)

[Thurberg BL, et al, Efficacy of olipudase alfa in NPD-B (2021)](https://doi.org/10.1016/j.ymgme.2020.12.148)

[Kim S, et al, Pulmonary outcomes in olipudase alfa trial (2022)](https://doi.org/10.1186/s12931-022-01965-1)

[Patterson MC, et al, Lipid profile changes with olipudase alfa (2022)](https://doi.org/10.1016/j.jlr.2022.100175)

[Jones SA, et al, Growth effects of olipudase alfa (2022)](https://doi.org/10.1016/j.jpeds.2021.08.082)

[Platt FM, et al, Blood-brain barrier in enzyme therapy (2021)](https://doi.org/10.1002/jimd.12317)

[Thurberg BL, et al, Clinical trial results of olipudase alfa (2022)](https://doi.org/10.1002/jcph.1976)

Unknown, European Medicines Agency. Miglustat (Zavesca). Product information. 2021 (2021)

[Platt FM, et al, Miglustat: mechanism of action (2019)](https://doi.org/10.1016/j.ymgme.2019.01.015)

[Lachmann RH, Miglustat: clinical practice guidelines (2019)](https://doi.org/10.1002/jimd.12099)

[Patterson MC, et al, Miglustat for Niemann-Pick disease type C (2020)](https://doi.org/10.1212/WNL.0000000000009992)

[Cole JA, et al, Miglustat and eye movements in NPC (2021)](https://doi.org/10.1007/s00415-021-10418-8)

[Jiang X, et al, Biomarker response to miglustat in NPC (2020)](https://doi.org/10.1016/j.ymgme.2020.03.003)

[Evans WR, et al, Early miglustat treatment in NPC (2021)](https://doi.org/10.1002/jimd.12376)

[Lachmann RH, et al, Miglustat side effects (2014)](https://doi.org/10.1007/s10545-013-9645-0)

[Héron B, et al, Management of neurological symptoms in NPC (2013)](https://doi.org/10.1016/B978-0-444-59565-2.00033-0)

[Wraith JE, et al, Supportive care in Niemann-Pick disease (2010)](https://doi.org/10.1007/s10545-010-9143-1)

[Patterson MC, et al, Recommendations for monitoring NPC patients (2019)](https://doi.org/10.1007/s10545-019-0410-0)

[Chandler RJ, et al, Gene therapy for Niemann-Pick disease (2021)](https://doi.org/10.1089/hum.2020.167)

[Dvorak-Ewell M, et al, Emerging therapies for NPD (2022)](https://doi.org/10.1016/j.ymgme.2021.12.006)

McGovern MM, et al, Pulmonary management in NPD (2019)

Mengel E, et al, Respiratory disease in NPD (2017)

Héron B, et al, Infections in NPD (2018)

McGovern MM, et al, Portal hypertension in NPD (2006)

Wasserstein MP, et al, Nutritional issues in NPD (2019)

Héron B, et al, Antiepileptic therapy in NPC (2019)

Wraith JE, et al, Physical therapy in lysosomal storage disorders (2018)

Gieselmann V, et al, Speech therapy in NPD (2020)

Jones SA, et al, Biochemical diagnosis of NPD (2015)

Wraith JE, et al, ASM activity assay (2010)

Porter FD, et al, Plasma oxysterols as biomarkers (2013)

Wijburg FA, et al, Chitotriosidase in NPC (2012)

Patterson MC, et al, Genetic testing for NPD (2011)

Schuchman EH, et al, SMPD1 sequencing (2009)

Unknown, NPC1 Consortium. NPC1 sequencing. Hum Mutat. 2006;27(10):1061-1062 (2006)

Runz H, et al, NPC2 sequencing (2008)

Saito Y, et al, Brain MRI findings in NPC (2011)

Hori H, et al, Abdominal ultrasound in NPD (2000)

Guillemot N, et al, Chest CT in NPD-B (2014)

Runz H, et al, Natural history of NPD-A (2008)

McGovern MM, et al, Disease-modifying therapy in NPD (2020)

Vite CH, et al, AAV gene therapy for NPD (2018)

Hughes MP, et al, CRISPR approaches to NPC (2019)

Liu MM, et al, Novel SRIs for NPC (2022)

Dodge JC, et al, BBB-crossing ASM (2021)

Wasserstein MP, et al, Genotype-phenotype in NPD (2018)

Patterson MC, et al, Early intervention in NPC (2020)

Héron B, et al, Biomarkers for NPD treatment response (2021)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-niemann-pick-disease-treatment

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-niemann-pick-disease-treatment
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-89bc5ffd1333
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-niemann-pick-disease-treatment'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

90%

Debates

0

Incoming

18

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Niemann-Pick Disease Treatment

Niemann-Pick Disease Treatment

Overview

Niemann-Pick Disease Treatment

Overview

Types of Niemann-Pick Disease

Niemann-Pick Type A

Niemann-Pick Type B

Niemann-Pick Type C

Epidemiology and Genetics

Prevalence

Genetic Basis

Pathophysiology

Acid Sphingomyelinase Deficiency

Cholesterol Trafficking Defects

Clinical Manifestations

NPD Type A [@cole2021]

NPD Type B [@jiang2020]

NPC [@evans2021]

Current Treatment Approaches

Enzyme Replacement Therapy

Substrate Reduction Therapy

Supportive Care

Emerging Therapies

Management of Specific Complications

Diagnosis

Biochemical Testing [@hron2021]

Genetic Testing [^104]

Imaging [^108]

Prognosis

NPD Type A

NPD Type B

NPC

Future Directions

Clinical Trials

Personalized Medicine

See Also

References

💬 Discussion

📗 Cite This Artifact

Niemann-Pick Disease Treatment

Niemann-Pick Disease Treatment

Overview

Niemann-Pick Disease Treatment

Overview

Types of Niemann-Pick Disease

Niemann-Pick Type A

Niemann-Pick Type B

Niemann-Pick Type C

Epidemiology and Genetics

Prevalence

Genetic Basis

Pathophysiology

Acid Sphingomyelinase Deficiency

Cholesterol Trafficking Defects

Clinical Manifestations

NPD Type A [@cole2021]

NPD Type B [@jiang2020]

NPC [@evans2021]

Current Treatment Approaches

Enzyme Replacement Therapy

Substrate Reduction Therapy

Supportive Care

Emerging Therapies

Management of Specific Complications

Diagnosis

Biochemical Testing [@hron2021]

Genetic Testing [^104]

Imaging [^108]

Prognosis

NPD Type A

NPD Type B

NPC

Future Directions

Clinical Trials

Personalized Medicine

See Also

References

Related Hypotheses

💬 Discussion